Cardiovascular risk with androgen deprivation therapy
- 22 November 2019
- journal article
- research article
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 74 (3) , e13449
Abstract
Background From the primary care perspective, many urologists and oncologists appear to be ignoring an FDA warning to assess patients' cardiovascular (CV) risk before instituting androgen deprivation therapy (ADT) with gonadotropin‐releasing hormone (GnRH) agonists. A growing body of data suggests an association between androgen deprivation therapy (ADT) and CV/cardiometabolic risk, particularly for GnRH agonists. Methodology The author examined available evidence regarding CV side effects with GnRH agonists and antagonists to determine what urologists, medical oncologists, primary care physicians (PCPs), and patients need to know about these risks. Results Data are inconclusive and somewhat conflicting — both low testosterone and testosterone replacement have been associated with elevated CV risk, for example. But the distinction between GnRH agonists and antagonists is becoming clearer, as agonists appear to be more strongly linked with CV risk, perhaps due to the transient testosterone surge they cause upon administration. Moreover, adverse CV events associated with GnRH agonists can emerge relatively quickly, within weeks to months. Conversely, two studies show that GnRH antagonists may significantly reduce CV risk compared to GnRH agonists. Conclusions Both GnRH agonists and antagonists carry some degree of CV risk. Although the risk appears to be lower with GnRH antagonists, urologists and oncologists should communicate with PCPs to determine patients' baseline CV risk levels before implementing ADT with either type of agent.Keywords
Funding Information
- Ferring
This publication has 35 references indexed in Scilit:
- Expression of follicle-stimulating hormone receptor by the vascular endothelium in tumor metastasesBMC Cancer, 2013
- Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trialsBMC Medicine, 2013
- Risk Factors Associated With Cardiovascular Events During Testosterone Administration in Older Men With Mobility LimitationThe Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 2012
- Endogenous Testosterone and Mortality in Men: A Systematic Review and Meta-AnalysisThe Journal of Clinical Endocrinology & Metabolism, 2011
- Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysisHeart, 2010
- Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular RiskCirculation, 2010
- HORMONE-REFRACTORY PROSTATE CANCER CELLS EXPRESS FUNCTIONAL FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR)Journal of Urology, 1999
- Human Peripheral Blood Mononuclear Cells Express Gonadotropin-Releasing Hormone (GnRH), GnRH Receptor, and Interleukin-2 Receptor -Chain Messenger Ribonucleic Acids That Are Regulated by GnRH in VitroThe Journal of Clinical Endocrinology & Metabolism, 1999
- Prostate—an extrapituitary source of follicle‐stimulating hormone (FSH): Occurrence, localization, and de novo biosynthesis and its hormonal modulation in primates and rodentsThe Prostate, 1991
- Morphologic features of unstable atherothrombotic plaques underlying acute coronary syndromesThe American Journal of Cardiology, 1989